Recurrent pneumothorax in a patient with liposarcoma as either a complication of lung micrometastasis or a potential adverse event from antibiotic therapy: A case report

Monti,Manlio; Sullo,Francesco Giulio; Iamurri,Andrea Prochowski; Gianni,Caterina; Silimbani,Paolo; Bartolini,Giulia; Valgiusti,Martina; Esposito,Luca; Montanari,Daniela; Antonini,Stefano; Frassineti,Giovanni Luca

doi:10.3892/ol.2022.13324

Recurrent pneumothorax in a patient with liposarcoma as either a complication of lung micrometastasis or a potential adverse event from antibiotic therapy: A case report

Authors:
- Manlio Monti
- Francesco Giulio Sullo
- Andrea Prochowski Iamurri
- Caterina Gianni
- Paolo Silimbani
- Giulia Bartolini
- Martina Valgiusti
- Luca Esposito
- Daniela Montanari
- Stefano Antonini
- Giovanni Luca Frassineti
View Affiliations

Affiliations: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, I‑47014 Meldola, Italy, Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, I‑47014 Meldola, Italy, Oncology Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ‘Dino Amadori’, I‑47014 Meldola, Italy
Published online on: May 12, 2022 https://doi.org/10.3892/ol.2022.13324
Article Number: 202
Copyright: © Monti et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Spontaneous pneumothorax (PNX) is an infrequent manifestation of primary lung cancer, soft tissue sarcoma and metastasis. There are no easily accessible data in the literature regarding the correlation between PNX and antibiotics, whereas cases of PNX following chemotherapy have been observed. Only 1‑10% of treatment‑related adverse events are estimated to be reported to the Food and Drug Administration. The present study described a case of PNX of the left lung in a 70‑year‑old treatment‑naive patient with retroperitoneal liposarcoma. The PNX developed after 8 days of treatment with levofloxacin and after 6 days of piperacillin/tazobactam treatment for a suspicious inflammatory area in the right lung detected by an FDG‑PET scan before the patient started chemotherapy. A chest CT scan confirmed the presence of metastasis in the right lung, but neither FDG‑PET/CT nor CT showed metastatic disease in the left lung. A total of 14 days after the end of the third cycle of doxorubicin (2 months after the initial diagnosis of PNX), the patient manifested a massive PNX of the right lung. In conclusion, these findings indicated that spontaneous PNX could be linked to the use of some antibiotics.

View Figures

View References

1	Lopes P, Nunes T, Campos D, Furlong LI, Bauer-Mehren A, Sanz F, Carrascosa MC, Mestres J, Kors J, Singh B, et al: Gathering and exploring scientific knowledge in pharmacovigilance. PLoS One. 8:e830162013. View Article : Google Scholar : PubMed/NCBI
2	Silverman SL: From randomized controlled trials to observational studies. Am J Med. 122:114–120. 2009. View Article : Google Scholar : PubMed/NCBI
3	Alves C, Macedo AF and Marques FB: Sources of information used by regulatory agencies on the generation of drug safety alerts. Eur J Clin Pharmacol. 69:2083–2094. 2013. View Article : Google Scholar
4	Pal SN, Duncombe C, Falzon D and Olsson S: WHO strategy for collecting safety data in public health programmes: Complementing spontaneous reporting systems. Drug Saf. 36:75–81. 2013. View Article : Google Scholar : PubMed/NCBI
5	Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 30:239–245. 1981. View Article : Google Scholar : PubMed/NCBI
6	Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, et al: Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 51:260–277. 2013. View Article : Google Scholar : PubMed/NCBI
7	Agbabiaka TB, Savović J and Ernst E: Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf. 31:21–37. 2008. View Article : Google Scholar : PubMed/NCBI
8	Khan LM, Al-Harthi SE, Osman AM, Sattar MA and Ali AS: Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J. 24:485–493. 2016. View Article : Google Scholar : PubMed/NCBI
9	Kalghatgi S, Spina CS, Costello JC, Liesa M, Morones-Ramirez JR, Slomovic S, Molina A, Shirihai OS and Collins JJ: Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. Sci Transl Med. 5:192ra852013. View Article : Google Scholar : PubMed/NCBI
10	Wang X, Zhao X, Malik M and Drlica K: Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother. 65:520–524. 2010. View Article : Google Scholar : PubMed/NCBI
11	Costumbrado J and Ghassemzadeh S: Spontaneous pneumothorax. StatPearls. StatPearls Publishing; Treasure Island, FL: 2022
12	Ciriaco P, Rossetti F, Carretta A, Sant'Angelo M, Arrigoni G and Negri G: Spontaneous pneumothorax in cocaine users. QJM. 112:519–522. 2019. View Article : Google Scholar : PubMed/NCBI
13	Bennett AC, Bennett CL, Witherspoon BJ and Knopf KB: An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency. Expert Opin Drug Saf. 18:1055–1063. 2019. View Article : Google Scholar : PubMed/NCBI
14	Reviglio VE, Hakim MA, Song JK and O'Brien TP: Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. BMC Ophthalmol. 3:102003. View Article : Google Scholar
15	Guzzardi DG, Teng G, Kang S, Geeraert PJ, Pattar SS, Svystonyuk DA, Belke DD and Fedak PWM: Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation: A potential mechanism of fluoroquinolone-associated aortopathy. J Thorac Cardiovasc Surg. 157:109–119.e2. 2019. View Article : Google Scholar : PubMed/NCBI
16	Tsai WC, Hsu CC, Chen CP, Chang HN, Wong AM, Lin MS and Pang JH: Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res. 29:67–73. 2011. View Article : Google Scholar : PubMed/NCBI
17	Berillis P: The role of collagen in the aorta structure. Open Circ Vasc J. 6:1–8. 2013. View Article : Google Scholar
18	Gelse K, Pöschl E and Aigner T: Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev. 55:1531–1546. 2003. View Article : Google Scholar : PubMed/NCBI
19	Fujimori K, Shimatsu Y, Suzuki E, Arakawa M and Gejyo F: Levofloxacin-induced eosinophilic pneumonia complicated by bronchial asthma. Nihon Kokyuki Gakkai Zasshi. 38:385–390. 2000.(In Japanese).
20	Tohyama M, Arakaki N, Tamaki K and Shimoji T: A case of drug-induced pneumonitis due to levofloxacin and kampo medicine. Nihon Kokyuki Gakkai Zasshi. 44:951–956. 2006.(In Japanese).
21	Shibusa T and Onuma K: A case of possible drug-induced lung injury caused by levofloxacin. Nihon Kyoubu Rinsho. 74:691–696. 2015.(In Japanese).
22	Facciolongo N, Menzella F, Castagnetti C, Cavazza A, Piro R, Carbonelli C and Zucchi L: Eosinophilic infiltrate in a patient with severe Legionella pneumonia as a levofloxacin-related complication: A case report. J Med Case Rep. 4:3602010. View Article : Google Scholar : PubMed/NCBI
23	Hosogaya N, Toida K, Ishihara H and Kugiyama K: A case of drug induced lung injury caused by levofloxacin eye drops. Respir Med Case Rep. 24:12–15. 2018.PubMed/NCBI
24	Steiger D, Bubendorf L, Oberholzer M, Tamm M and Leuppi JD: Ciprofloxacin-induced acute interstitial pneumonitis. Eur Respir J. 23:172–174. 2004. View Article : Google Scholar : PubMed/NCBI
25	Kimura N, Miyazaki E, Matsuno O, Abe Y and Tsuda T: Drug-induced pneumonitis with eosinophilic infiltration due to tosufloxacin tosilate. Nihon Kokyuki Gakkai Zasshi. 36:618–622. 1998.(In Japanese).
26	USA Food and Drug Administration, Department of Health and Human Services, . NDA approval No. 050684/S-055S-061050750/S-016, S-020. Available from. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/050684s061,050750s016ltr.pdf
27	Graf-Deuel E and Knoblauch A: Simultaneous bilateral spontaneous pneumothorax. Chest. 105:1142–1146. 1994. View Article : Google Scholar
28	Upadya A, Amoateng-Adjepong Y and Haddad RG: Recurrent bilateral spontaneous pneumothorax complicating chemotherapy for metastatic sarcoma. South Med J. 96:821–823. 2003. View Article : Google Scholar : PubMed/NCBI
29	Lee CH, Park KU, Nah DY and Won KS: Bilateral spontaneous pneumothorax during cytotoxic chemotherapy for angiosarcoma of the scalp: A case report. J Korean Med Sci. 18:277–280. 2003. View Article : Google Scholar
30	Matsuura Y, Ninomiya H, Ichinose J, Nakao M, Ishikawa Y, Okumura S and Mun M: Pathogenesis of secondary spontaneous pneumothorax complicating osteosarcoma. Ann Thorac Surg. 110:e81–e83. 2020. View Article : Google Scholar : PubMed/NCBI
31	Boone PM, Scott RM, Marciniak SJ, Henske EP and Raby BA: The genetics of pneumothorax. Am J Respir Crit Care Med. 199:1344–1357. 2019. View Article : Google Scholar : PubMed/NCBI
32	Cheng YL, Huang TW, Lin CK, Lee SC, Tzao C, Chen JC and Chang H: The impact of smoking in primary spontaneous pneumothorax. J Thorac Cardiovasc Surg. 138:192–195. 2009. View Article : Google Scholar : PubMed/NCBI
33	Kim D, Eom SY, Shin CS, Kim YD, Kim SW and Hong JM: The clinical effect of smoking and environmental factors in spontaneous pneumothorax: A case-crossover study in an Inland province. Ther Adv Respir Dis. 14:17534666209774082020. View Article : Google Scholar : PubMed/NCBI